QNZ NEW
| Price | $36 | $52 | $85 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: QNZ | CAS No.: 545380-34-5 |
| Purity: 99.17% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | QNZ |
| Description | QNZ (EVP4593) (EVP4593) is an effective inhibitor of NF-κB activation and TNF-α production. The IC50 of QNZ for NF-κB and TNF-α is11 nM and 7 nM, respectively. |
| In vitro | Intraperitoneal injection of EVP4593 (1 mg/kg) in rats suppressed carrageenan-induced paw edema in a dose-dependent manner. |
| In vivo | In murine spleen cells stimulated by lipopolysaccharide, EVP4593 (IC50= nM) inhibits the production of TNF-α. In rat neutrophils, EVP4593 (10 nM) suppresses the upregulation of CSE expression induced by lipopolysaccharide. EVP4593 (40 nM) entirely inhibits the increase in the number and length of axons during laminin treatment in Schwann cell adhesion. Additionally, in IB4-negative neurons, EVP4593 (100 nM) blocks the induction effect of GRO/KC on K currents. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 5 mg/mL (14.02 mM) |
| Keywords | TNFR | NF-κB | CAY-10470 | EVP-4593 | Inhibitor | Nuclear factor-kappaB | EVP 4593 | QNZ | inhibit | Tumor Necrosis Factor Receptor | Nuclear factor-κB | CAY 10470 | TNF Receptor |
| Inhibitors Related | Acetylcysteine | Lidocaine | Diethylmaleate | Glucosamine | sodium lauroyl-α-hydroxyethyl sulfonate | Lidocaine hydrochloride | Apremilast | 5-Aminosalicylic Acid | Indole-3-carbinol | Lenalidomide | Diallyl disulfide | Sodium salicylate |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Diabetic Compound Library | Anti-Ovarian Cancer Compound Library | Neuroprotective Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-COVID-19 Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.01/1KG |
VIP5Y
|
Career Henan Chemica Co
|
2020-10-28 | |
| $0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-08-29 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY